Anaptysbio, Inc 8-K Filing

FAQ

Key Financial Figures

• $0.001 — ich registered Common stock, par value $0.001 per share ANAB The Nasdaq Stock Mar
• $13.81 — o the Investors, at a purchase price of $13.81 per share (the "Private Placement"). Th
• $80 m — Shares is expected to be approximately $80 million, before deducting offering expens
• $100.0 million — which the Company may repurchase up to $100.0 million of the Company's outstanding common sto

Filing Documents

• d122216d8k.htm (8-K) — 47KB
• d122216dex101.htm (EX-10.1) — 199KB
• d122216dex102.htm (EX-10.2) — 124KB
• d122216dex991.htm (EX-99.1) — 21KB
• d122216dex992.htm (EX-99.2) — 8KB
• d122216dex993.htm (EX-99.3) — 18KB
• 0001193125-26-127783.txt ( ) — 635KB
• anab-20260326.xsd (EX-101.SCH) — 3KB
• anab-20260326_lab.xml (EX-101.LAB) — 18KB
• anab-20260326_pre.xml (EX-101.PRE) — 11KB
• d122216d8k_htm.xml (XML) — 4KB

Forward-Looking Statements

Forward-Looking Statements This communication contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited to: statements relating to plans for executing the Spin-Off, the expected timing of the Spin-Off, the expected financial operations and condition of AnaptysBio and First Tracks Biotherapeutics following the Spin-Off, the strategies, plans and objectives of AnaptysBio and First Tracks Biotherapeutics following the Spin-Off, statements relating to the expected timing of closing of the Private Placement, the company's ability to execute the Stock Repurchase Plan, in whole or in part. Statements including words such as "plan," "continue," "expect," or "ongoing" and statements in the future tense are forward-looking statements. These forward-looking statements involve risks and uncertainties, as well as assumptions, which, if they do not fully materialize or prove incorrect, could cause its results to differ materially from those expressed or implied by such forward-looking statements. Forward-looking statements are subject to risks and uncertainties that may cause the company's actual activities or results to differ significantly from those expressed in any forward-looking statement, including risks and uncertainties related to the company's ability to advance its product candidates, obtain regulatory approval of and ultimately commercialize its product candidates, the timing and results of preclinical and clinical trials, the company's ability to fund development activities and achieve development goals, the company's ability to protect intellectual property, the ability to effect the separation of companies as described herein and other risks and uncertainties described under the heading "Risk Factors" in documents the company files from time to time with the Securities and Exchange Commission. These forward-looking statements speak only as of the date

Financial Statements and Exhibits

Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 10.1 Purchase Agreement, dated as of March 26, 2026, by and among SpinCo, the Selling Stockholder and the Investors party thereto. 10.2 Form of Registration Rights Agreement. 99.1 Press Release, dated March 27, 2026, relating to the Spin-Off. 99.2 Press Release, dated March 27, 2026, relating to the Private Placement. 99.3 Press Release, dated March 27, 2026, relating to the AnaptysBio Stock Repurchase Plan. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: March 27, 2026 ANAPTYSBIO, INC. By: /s/ Dan Faga Dan Faga President and Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR